Yıl: 2015 Cilt: 25 Sayı: 4 Sayfa Aralığı: 407 - 428 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

New targets for the management of schizophrenia

Öz:
Schizophrenia is characterized by abnormal mental functions and disturbed behavior. The diagnosis of schizophrenia is based on criteria defined in either the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, version DSM-IV (2) or the ICD-10. Targets of treatment include positive and negative symptoms, depression, suicidal ideation and behaviors, substance use disorders, medical comorbidities, posttraumatic stress disorder, and community adjustment problems. The first-generation antipsychotics were first introduced for the treatment of schizophrenia in the 1950s. The introduction of second-generation antipsychotics (SGAs) in the last three decades improved the desired effects of these medications with a reduction of their undesirable effects such as extrapyramidal adverse effects, mortality and metabolic disorder. Medication is generally helpful in treating positive symptoms, but up to a third of people derive little benefit, and negative symptoms are difficult to treat. It has been shown that lack of efficacy and tolerability, often associated with poor compliance, results in treatment discontinuation or treatment switch. Despite critical importance of medication for patients with schizophrenia, nonadherence to treatment is an important issue worldwide. The most prominent patient-related factors associated with nonadherence included lack of insight into the need for medication, denial of illness, embarrassment and unsuitable living conditions. Although antipsychotic medications are necessary, they are not sufficient for the treatment of schizophrenia. The cognitive therapy (cognitive behavioral therapy and cognitive remediation therapy), social skills, psychoeducation programs, family intervention, training programs, and case management or assertive community treatment are the major categories of psychosocial intervention which is an important part of the disease management. The major considerations in disease management treatment include the comprehensive and continuous treatment for prolonged periods, integrated, bio-psychosocial approach to care, active collaboration with the family while planning and delivering treatment and treatment sensitive to the patient's needs and empirically titrated to the patient's response and progress.
Anahtar Kelime:

Konular: Farmakoloji ve Eczacılık
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1.Dominguez Mde G, Viechtbauer W, Simons CJ, van Os J, Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull 2009;135(1):157-71. [CrossRef]
  • 2.American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders-(DSM-IV), 4thedition. American Psychiatric Association, Washington, DC
  • .3. Jablensky A. Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. Aust N Z J Psychiatry 2000;34(Suppl):S26-S34. [CrossRef]
  • 4. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000;250(6):274-85. [CrossRef]
  • 5. Pulver AE. Search for schizophrenia susceptibility genes. Biol Psychiatry 2000;47(3):221-30. [CrossRef]
  • 6. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al.; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(Suppl.2):S1-S56.
  • 7. McGrath J, Saha S, Welham J, El-Saadi O, MacCauley C, Chant D. A systemic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004;2:13. [CrossRef]
  • 8. Jones P. The early origins of schizophrenia. Br Med Bull 1997;53(1):135-55. [CrossRef]
  • 9. McGlashan TH. Early detection and intervention in schizophrenia: research. Schizophr Bull 1996;22(2):327-45. [CrossRef]
  • 10. Yung AR, McGorry PD. The prodromal phase of first-episodepsychosis: past and current conceptualizations. Schizophr Bull 1996;22(2):353-70. [CrossRef]
  • 11. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997;17(4):205-29. [CrossRef]
  • 12. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56(3):241-7. [CrossRef] 13. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64(10):1123-31. [CrossRef
  • ]14. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171(6):502-8. [CrossRef]
  • 15. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted Country, Minnesota cohort:1950-2005. Schizophr Res 2008;98(1-3):287-94. [CrossRef]
  • 16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23. [CrossRef]
  • 17. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006;36(10):1349-62. [CrossRef]
  • 18. Jääskeläinen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013;39(6):1296-306. [CrossRef]
  • 19. International Classification of Mental and Behavioral Disorders. Clinical descriptions and diagnostic guidelines. 10th edition, World Health Organization (http://www.who.int/classifications/icd/en/).
  • 20. Jakobsen KD, Frederiksen JN, Hansen T, Jansson LB, Parnas J, Werge T. Reliability of clinical ICD-10 schizophrenia diagnoses. Nord J Psychiatry 2005;59(3):209-12. [CrossRef]
  • 21. Kraepelin E. Dementia praecox and paraprenia, 1919. In: Robertson, GM (Ed), Krieger, New York.
  • 22. Bleuler E. 1950. Dementia praecox, or the group of schizophrenias. 1911. Translated by J. Zinkin International University Press, New York.
  • 23. Schneider K. 1959. Clinical psychopathology. Translated by Hamilton MW Grune and Stratton, New York.
  • 24. Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013;150(1):3-10. [CrossRef]
  • 25. Bitter I, Katona L, Zambori J, Takács P, Fehér L, Diels J, et al. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol 2013;23(11):1383-90. [CrossRef]
  • 26. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995;46(10):1049-54. [CrossRef]
  • 27. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21(3):419-29. [CrossRef]
  • 28. Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ 2013;16(11):1290-9. [CrossRef]
  • 29. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74(10):957-65. [CrossRef]
  • 30. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(8):1042-8. [CrossRef]
  • 31. Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010;11(14):2301-17. [CrossRef]
  • 32. Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6(1):41-53. [CrossRef]
  • 33. Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010;26(3):501-9. [CrossRef]
  • 34. Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013;16(2):231-9. [CrossRef]
  • 35. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011;3:9-14.
  • 36. Kim S, Solari H, Weiden PJ, Bishop JR. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Prefer Adherence 2012;6: 533-45.
  • 37. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2013;18(1):53-66. [CrossRef]
  • 38. Waddington JL, Youssef HA, Kinsella A. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol Med 1995;25(4):849-57. [CrossRef]
  • 39. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149(9):1183-8. [CrossRef]
  • 40. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17(2):325-51. [CrossRef]
  • 41. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996;22(2):241-56. [CrossRef]
  • 42. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996;22(2):305-26. [CrossRef]
  • 43. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 2013;3(4):200-18. [CrossRef]
  • 44. Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry 2004;65(2):211-6. [CrossRef]
  • 45. Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012;12:20. [CrossRef]
  • 46. Koyze AM, van Delft WF, Roos JL. Continity of care of ourpatients with schizophrenia in Pretoria. S Afr J Psychiatr 2010;16(3):80-83.
  • 47. Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compli¬ance with antipsychotic medication is common in patients with schizophrenia. Aust N Z J Psychiatry 2008;42(5):382-8. [CrossRef]
  • 48. Zeber JE, Grazier KL, Valenstein M, Blow FC, Lantz PM. Effect of medication copayment increase in veterans with schizophrenia. Am J Manag Care 2007;13(6 Pt 2):335-46.
  • 49. Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry 2004;65(9):1211-8. [CrossRef]
  • 50. Löffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003;36(3):105-12. [CrossRef]
  • 51. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl. 4):1-46; quiz 47-8. [CrossRef
  • ]52. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10(Suppl. 3):105-14.
  • 53. IMS Health, Retail & Provider Perspective, December 2002.
  • 54. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30. [CrossRef]
  • 55. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl.7):S22-S31.
  • 56. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5(4):437-40. [CrossRef]
  • 57. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(Suppl.10):S45-S9.
  • 58. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159(2):255-62. [CrossRef]
  • 59. Csernansky JG, Mahmoud R, Brenner R; Risperidone USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346(1):16-22. [CrossRef
  • ]60. Brecher M, Rak IW, Melvin K, Jones AM.. The long-term effect of quetiapine (Seroquel TM) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4(4):287-91. [CrossRef]
  • 61. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63(6):516-23. [CrossRef]
  • 62. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6(4):325-37. [CrossRef]
  • 63. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170(8):463-7. [CrossRef]
  • 64. Bobes J, Garc A-Portilla MP, Rejas J, Hernandez G, Garcia-Garcia M, Rico-Villademoros F, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29(2):125-47. [CrossRef]
  • 65. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159(1):133-5. [CrossRef]
  • 66. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57-61. [CrossRef]
  • 67. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Anderson SW, Beasley C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-18. [CrossRef]
  • 68. Arvenitis L, Miller B. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42(4):233-46. [CrossRef]
  • 69. Gahr M, Kölle MA, Schönfeldt-Lecuona C, Lepping P, Freudenmann RW. Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Des Devel Ther. 2011;5:125-46. [CrossRef]
  • 70. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA). Schizophr Res 2006;84(1):77-89. [CrossRef]
  • 71. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008;69(Suppl 1):S4-S17.
  • 72. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 2009;107(1):22-9. [CrossRef]
  • 73. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64(5):580-8. [CrossRef]
  • 74. Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004;9(5):357-64.
  • 75. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002;63(10):931-5. [CrossRef]
  • 76. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D; Study 147 Investigators. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008;24(1):21-32. [CrossRef]
  • 77. De Nayer A, Windhager E, Irmansyah E, Larmo I, Lindenbauer B, Rittmannsberger H, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003;7(1):59-66. [CrossRef]
  • 78. Weiden PJ. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 2006;20(1):104-18. [CrossRef]79. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13(1):13-24. [CrossRef]
  • 80. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al.; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13(5):318-78. [CrossRef]
  • 81. Leucht S, Heres S, Kissling W, Davis JM. Pharmacological treatment of schizophrenia. Fortschr Neurol Psychiatr 2013;81(5):e1e13.
  • 82. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010;197(3):174-9. [CrossRef]
  • 83. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al.; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36(1):71-93. [CrossRef]
  • 84. Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25(5):567-620. [CrossRef]
  • 85. Storosum JG, Elferink AJ, van Zwieten BJ, van Strik R, Hoogendijk WJ, Broekmans AW. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull 2002;28(2):193-201. [CrossRef]
  • 86. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009;39(10):1591-602. [CrossRef]
  • 87. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55(5):452-6. [CrossRef]
  • 88. Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 2013;150(2-3):434-41. [CrossRef]
  • 89. EnVivo Pharmaceuticals. EnVivo Pharmaceuticals presents positive comprehensive phase 2b study results in schizophrenia at American College of Neuropsychopharmacology annual meeting [press release]; December 5, 2011. Available from: http://www.envivopharma.com/news-item.php?id=35. Accessed January, 2015.90. Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry 2013;203(3):172-8. [CrossRef]
  • 91. Lindenmayer JP, Nasrallah H, Pucci M, James S, Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res 2013;147(2-3):241-52. [CrossRef]
  • 92. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symp¬toms in patients with schizophrenia: an update. Schizophr Bull 2014;40(1):181-91. [CrossRef
  • ]93. Kishi T, Mukai T, Matsuda Y, Iwata N. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Neuromolecular Med 2014;16(1):61-9. [CrossRef]
  • 94. Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009;34(8):1885-903. [CrossRef]
  • 95. Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 2011;191:78-90. [CrossRef]
  • 96. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, et al.; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010;36(1):48-70. [CrossRef]
  • 97. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 2002;32(5):763-82. [CrossRef]
  • 98. Rathod S, Turkington D. Cognitive-behaviour therapy for schizophrenia: a review. Curr Opin Psychiatry 2005;18(2):159-63. [CrossRef]
  • 99. Tarrier N, Kinney C, McCarthy E, Humphreys L, Wittkowski A, Morris J. Two-year follow-up of cognitive - behavioral therapy and supportive counseling in the treatment of persistent symptoms in chronic schizophrenia. J Consult Clin Psychol 2000;68(5):917-22. [CrossRef]
  • 100. Thornicroft G, Susser E. Evidence-based psychotherapeutic interventions in the community care of schizophrenia. Br J Psychiatry 2001;178(1):2-4. [CrossRef]
  • 101. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008;34(3):523-37. [CrossRef]
  • 102. Lecomte T, Leclerc C, Corbière M, Wykes T, Wallace CJ, Spidel A. Group cognitive behavior therapy or social skills training for individuals with a recent onset of psychosis? Results of a randomized controlled trial. J Nerv Ment Dis 2008;196(12):866-75. [CrossRef]
  • 103. Gumley A, O'Grady M, McNay L, Reilly J, Power K, Norrie J. Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. Psychol Med 2003;33(3):419-31. [CrossRef]
  • 104. Durham RC, Guthrie M, Morton RV, Reid DA, Treliving LR, Fowler D, et al. Tayside-Fife clinical trial of cognitive-behavioural therapy for medication-resistant psychotic symptoms. Results to 3-month follow-up. Br J Psychiatry 2003;182:303-11. [CrossRef]
  • 105. Gould RA, Mueser KT, Bolton E, Mays V, Goff D. Cognitive therapy for psychosis in schizophrenia: an effect size analysis. Schizophr Res 2001;48(2-3):335-42. [CrossRef]
  • 106. Jones C, Hacker D, Meaden A, Cormac I, Irving CB. WITHDRAWN: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev 2011;(4):CD000524.
  • 107. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158(10):1706-13. [CrossRef]
  • 108. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011;125(1):54-61. [CrossRef]
  • 109. Kay T. Neuropsychological treatment of mild traumatic brain injury. The Journal of Head Trauma Rehabilitation 1993;8:74-85. [CrossRef]
  • 110. Elgamal S, McKinnon MC, Ramakrishnan K, Joffe RT, MacQueen G. Successful computer-assisted cognitive remediation therapy in patients with unipolar depression: a proof of principle study. Psychol Med 2007;37(9):1229-38. [CrossRef]
  • 111. Lask B. Cognitive Remediation Therapy. Eating Disorders in Childhood and Adolescence 2013:301.
  • 112. Hodge MA, Siciliano D, Withey P, Moss B, Moore G, Judd G, et al. A randomized controlled trial of cognitive remediation in schizophrenia. Schizophr Bull 2010;36(2):419-27. [CrossRef]
  • 113. Eack SM, Mesholam-Gately RI, Greenwald DP, Hogarty SS, Keshavan MS. Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement Therapy. Psychiatry Res 2013;209(1):21-6. [CrossRef]
  • 114. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007;164(12):1791-802. [CrossRef]
  • 115. Liberman RP, Wallace CJ, Blackwell G, Kopelowicz A, Vaccaro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. Am J Psychiatry 1998;155(8):1087-91. [CrossRef]
  • 116. Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clin Psychol Rev 2013;33(8):914-28. [CrossRef]
  • 117. Kurtz MM, Mueser KT. A meta-analysis of controlled research on social skills training for schizophrenia. J Consult Clin Psychol. 2008;76(3):491-504. [CrossRef]
  • 118. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005;62(7):717-24. [CrossRef]
  • 119. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Martindale B, et al. Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med 2002;32(5):783-91. [CrossRef]
  • 120. Kopelowicz A, Liberman RP, Zarate R. Recent advances in social skills training for schizophrenia. Schizophr Bull 2006;32(Suppl 1):S12-S23. [CrossRef]
  • 121. Glynn SM, Marder SR, Liberman RP, Blair K, Wirshing WC, Wirshing DA, et al. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry 2002;159(5):829-37. [CrossRef]
  • 122. Brooker C. A decade of evidence-based interventionsfor work with people with serious mental health problems: progress in the development of psychosocial interventions. Journal of Mental Health 2001;10:17-31. [CrossRef]
  • 123. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010;(12): CD000088. [CrossRef]
  • 124. Chien WT, Chan SW, Morrissey J. The perceived burden among Chinese family caregivers of people with schizophrenia. J Clin Nurs 2007;16(6):1151-61. [CrossRef]
  • 125. Magliano L, Fiorillo A, Malangone C, Marasco C, Guarneri M, Maj M; National Mental Health Project Working Group. The effect of social network on burden and pessimism in relatives of patients with schizophrenia. Am J Orthopsychiatry 2003;73(3):302-9. [CrossRef]
  • 126. Martens L, Addington J. The psychological well-being of family members of individuals with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2001;36(3):128-33. [CrossRef]
  • 127. National Institute for Health and Clinical Excellence Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care National Clinical Practice Guideline 82London, UK: National Institute for Health and Clinical Excellence; 2009. Available from: http://publications.nice.org.uk/schizophrenia-cg82.
  • 128. Rummel-Kluge C, Kissling W. Psychoeducation for patients with schizophrenia and their families.Expert Rev Neurother 2008;8(7):1067-77. [CrossRef]
  • 129. McFarlane WR, Dixon L, Lukens E, Lucksted A. Family psychoeducation and schizophrenia: a review of the literature. J Marital Fam Ther 2003;29(2):223-45. [CrossRef]
  • 130. Lucksted A, McFarlane W, Downing D, Dixon L. Recent developments in family psychoeducation as an evidence-based practice. J Marital Fam Ther 2012;38(1):101-21. [CrossRef]
  • 131. Solomon P. Interventions for families of individuals with schizophrenia: maximising outcomes for their relatives. Dis Manage Health Outcomes 2000;8:211-21. [CrossRef]
  • 132. Chien WT, Wong KF. A family psychoeducation group program for chinese people with schizophrenia in Hong Kong. Psychiatr Serv 2007;58(7):1003-6. [CrossRef]
  • 133. Li Z, Arthur D. Family education for people with schizophrenia in Beijing, China: randomised controlled trial. Br J Psychiatry 2005;187:339-45. [CrossRef]
  • 134. Stengård E. Educational intervention for the relatives of schizophrenia patients in Finland. Nord J Psychiatry 2003;57(4):271-7. [CrossRef]
  • 135. Dyck DG, Hendryx MS, Short RA, Voss WD, McFarlane WR. Service use among patients with schizophrenia in psychoeducational multiple-family group treatment. Psychiatr Serv 2002;53(6):749-54. [CrossRef]
  • 136. Glynn SM, Cohen AN, Dixon LB, Niv N. The potential impact of the recovery movement on family interventions for schizophrenia: opportunities and obstacles. Schizophr Bull 2006;32(3):451-63. [CrossRef]
  • 137. Anderson J, Adams C. Family interventions in schizophrenia. BMJ 1996;313(7056):505-6. [CrossRef]
  • 138. Drake RE, Bond GR, Essock SM. Implementing evidence-based practices for people with schizophrenia. Schizophr Bull 2009;35(4):704-13. [CrossRef]
  • 139. Stanley S, Shwetha S. Integrated psychosocial intervention in schizophrenia: implications for patients and caregivers. International Journal of Psychosocial Rehabilitation 2006;10:113-28.
  • 140. Burns T, Catty J, Dash M, Roberts C, Lockwood A, Marshall M. Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. BMJ 2007;335(7615):336. [CrossRef]
  • 141. Remington G, Foussias G, Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010;24(1):9-20. [CrossRef]
  • 142. Stein LI, Santos AB. Assertive Community Treatment of Persons with Severe Mental Illness. New York: Norton; 1998.
  • 143. Bond GR, Drake RE, Mueser KT, Latimer E. Assertive community treatment for people with severe mental illness: critical ingredients and impact on clients. Disease Management and Health Outcomes 2001;9(3):141-59. [CrossRef]
  • 144. Scott JE, Dixon LB. Assertive community treatment and case management for schizophrenia. Schizophr Bull 1995;21(4):657-68. [CrossRef]
  • 145. Harrison-Read P, Lucas B, Tyrer P, Ray J, Shipley K, Simmonds S, et al. Heavy users of acute psychiatric beds: randomized controlled trial of enhanced community management in an outer London borough. Psychol Med 2002;32(3):403-16. [CrossRef]
  • 146. Clarke GN, Herinckx HA, Kinney RF, Paulson RI, Cutler DL, Lewis K, et al. Psychiatric hospitalizations, arrests, emergency room visits, and homelessness of clients with serious and persistent mental illness: findings from a randomized trial of two ACT programs vs. usual care. Ment Health Serv Res 2000;2(3):155-64. [CrossRef]
APA DİLBAZ N (2015). New targets for the management of schizophrenia. , 407 - 428.
Chicago DİLBAZ Nesrin New targets for the management of schizophrenia. (2015): 407 - 428.
MLA DİLBAZ Nesrin New targets for the management of schizophrenia. , 2015, ss.407 - 428.
AMA DİLBAZ N New targets for the management of schizophrenia. . 2015; 407 - 428.
Vancouver DİLBAZ N New targets for the management of schizophrenia. . 2015; 407 - 428.
IEEE DİLBAZ N "New targets for the management of schizophrenia." , ss.407 - 428, 2015.
ISNAD DİLBAZ, Nesrin. "New targets for the management of schizophrenia". (2015), 407-428.
APA DİLBAZ N (2015). New targets for the management of schizophrenia. Klinik Psikofarmakoloji Bülteni, 25(4), 407 - 428.
Chicago DİLBAZ Nesrin New targets for the management of schizophrenia. Klinik Psikofarmakoloji Bülteni 25, no.4 (2015): 407 - 428.
MLA DİLBAZ Nesrin New targets for the management of schizophrenia. Klinik Psikofarmakoloji Bülteni, vol.25, no.4, 2015, ss.407 - 428.
AMA DİLBAZ N New targets for the management of schizophrenia. Klinik Psikofarmakoloji Bülteni. 2015; 25(4): 407 - 428.
Vancouver DİLBAZ N New targets for the management of schizophrenia. Klinik Psikofarmakoloji Bülteni. 2015; 25(4): 407 - 428.
IEEE DİLBAZ N "New targets for the management of schizophrenia." Klinik Psikofarmakoloji Bülteni, 25, ss.407 - 428, 2015.
ISNAD DİLBAZ, Nesrin. "New targets for the management of schizophrenia". Klinik Psikofarmakoloji Bülteni 25/4 (2015), 407-428.